#MSD's return to the #ophthalmology field after decades of absence, via the #acquisition of #EyeBio in a $3 billion deal in 2024, has been charged up with a positive phase 3 trial in #diabeticmacularoedema (DME).

pharmaphorum.com/news/wnt-dru...